• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    5 Value Stocks In The Healthcare Sector

    3/4/24 9:44:45 AM ET
    $BNTX
    $INVA
    $OGN
    $PROC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BNTX alert in real time by email

    The Meaning Behind Value Stocks

    A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.

    The following stocks are considered to be notable value stocks in the healthcare sector:

    1. Organon (NYSE:OGN) - P/E: 4.4
    2. BioNTech (NASDAQ:BNTX) - P/E: 7.47
    3. TherapeuticsMD (NASDAQ:TXMD) - P/E: 0.52
    4. Innoviva (NASDAQ:INVA) - P/E: 6.93
    5. Procaps Gr (NASDAQ:PROC) - P/E: 5.84

    Organon's earnings per share for Q4 sits at $0.88, whereas in Q3, they were at 0.87. The company's most recent dividend yield sits at 6.85%, which has decreased by 0.8% from 7.65% last quarter.

    BioNTech has reported Q3 earnings per share at $0.73, which has increased by 184.88% compared to Q2, which was -0.86. Most recently, TherapeuticsMD reported earnings per share at $-0.13, whereas in Q2 earnings per share sat at $-0.24. Innoviva's earnings per share for Q4 sits at $0.76, whereas in Q3, they were at 0.98. Procaps Gr saw a decrease in earnings per share from 0.27 in Q2 to $0.08 now.

    The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

    Get the next $BNTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNTX
    $INVA
    $OGN
    $PROC

    CompanyDatePrice TargetRatingAnalyst
    BioNTech SE
    $BNTX
    2/2/2026$113.00Outperform → Market Perform
    Leerink Partners
    BioNTech SE
    $BNTX
    1/16/2026$142.00Neutral → Buy
    Goldman
    Organon & Co.
    $OGN
    12/9/2025$7.50Underweight
    Barclays
    Organon & Co.
    $OGN
    10/27/2025$5.00Overweight → Underweight
    Piper Sandler
    Innoviva Inc.
    $INVA
    9/30/2025$17.00Sell
    Goldman
    Innoviva Inc.
    $INVA
    8/11/2025$45.00Outperform
    Oppenheimer
    Innoviva Inc.
    $INVA
    7/14/2025$40.00Buy
    H.C. Wainwright
    Innoviva Inc.
    $INVA
    7/11/2025$26.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $BNTX
    $INVA
    $OGN
    $PROC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Interim Head of Mfg & Supply Drinane Juliana Papa covered exercise/tax liability with 1,242 shares, decreasing direct ownership by 7% to 17,175 units (SEC Form 4)

    4/A - Organon & Co. (0001821825) (Issuer)

    1/16/26 4:37:45 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    12/29/25 4:23:31 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Basso Stephen was granted 604 shares and covered exercise/tax liability with 237 shares, increasing direct ownership by 0.72% to 51,257 units (SEC Form 4)

    4 - Innoviva, Inc. (0001080014) (Issuer)

    11/24/25 4:17:43 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $INVA
    $OGN
    $PROC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

    Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency Full year 2025 diluted earnings per share of $0.72 and non-GAAP Adjusted diluted earnings per share of $3.66 Full year 2025 Adjusted EBITDA of $1.91 billion inclusive of $6 million of IPR&D, representing a 30.7% Adjusted EBITDA margin The company expects to deliver approximately $6.2 billion of revenue and approximately $1.9 billion of Adjusted EBITDA for the full year 2026, both measures in-line with full year 2025 performance. Organon (NYSE:OGN) today announced its results for the fourth quarter and full year ended December 31, 2025. "In 2025 we took action that demonstrate

    2/12/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

    Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its fourth quarter and full year 2025 financial results on February 12, 2026, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the fourth quarter of 2025. Organon's fourth quarter and full year 2025 results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing Fourth Quarter and Full Year 2025 F

    1/29/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Completes Divestiture of JADA® System to Laborie

    Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp. Please see our prior announcement for a summary of the transaction terms. Indications for Use The JADA® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Contraindications Ongoing intrauterine pregnancy Untreated uterine rupture Unresolved uterine inversion Current cervical cancer Known uterine anomaly Current purulent infection o

    1/28/26 12:45:00 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $INVA
    $OGN
    $PROC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Innoviva Inc.

    SCHEDULE 13G/A - Innoviva, Inc. (0001080014) (Subject)

    2/12/26 2:14:30 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BioNTech SE

    144 - BioNTech SE (0001776985) (Subject)

    2/12/26 8:17:13 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Organon & Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Organon & Co. (0001821825) (Filer)

    2/12/26 7:45:44 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $INVA
    $OGN
    $PROC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

    12/29/21 7:23:57 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for IMVEXXY issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug IMVEXXY (SUPPL-2) with active ingredient ESTRADIOL has changed to 'Approval' on 11/16/2021. Application Category: NDA, Application Number: 208564, Application Classification: Labeling

    11/17/21 4:38:32 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-3) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 06/22/2021. Application Category: NDA, Application Number: 210132, Application Classification: Labeling

    6/24/21 5:13:50 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $INVA
    $OGN
    $PROC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioNTech downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00

    2/2/26 6:48:45 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech upgraded by Goldman with a new price target

    Goldman upgraded BioNTech from Neutral to Buy and set a new price target of $142.00

    1/16/26 8:19:35 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Organon with a new price target

    Barclays initiated coverage of Organon with a rating of Underweight and set a new price target of $7.50

    12/9/25 8:51:54 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $INVA
    $OGN
    $PROC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    12/29/25 4:23:31 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chair Cox Carrie Smith bought $501,755 worth of shares (65,400 units at $7.67) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    11/13/25 4:05:10 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cox Carrie Smith bought $100,591 worth of shares (12,469 units at $8.07) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/15/25 4:09:09 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $INVA
    $OGN
    $PROC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    12/3/24 7:20:10 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Innoviva Inc.

    SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)

    11/14/24 4:17:40 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioNTech SE

    SC 13G/A - BioNTech SE (0001776985) (Subject)

    11/13/24 5:00:57 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $INVA
    $OGN
    $PROC
    Leadership Updates

    Live Leadership Updates

    View All

    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

    Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin

    1/28/26 8:00:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BioNTech to Host Innovation Series R&D Day on November 11, 2025

    MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00 p.m. CET) on Tuesday, November 11, 2025 in New York City, U.S. On the day, members of BioNTech's leadership team will provide an overview of the Company's strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via this link. A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company's website for one year following the call. The public may also

    10/28/25 7:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $INVA
    $OGN
    $PROC
    Financials

    Live finance-specific insights

    View All

    Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

    Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency Full year 2025 diluted earnings per share of $0.72 and non-GAAP Adjusted diluted earnings per share of $3.66 Full year 2025 Adjusted EBITDA of $1.91 billion inclusive of $6 million of IPR&D, representing a 30.7% Adjusted EBITDA margin The company expects to deliver approximately $6.2 billion of revenue and approximately $1.9 billion of Adjusted EBITDA for the full year 2026, both measures in-line with full year 2025 performance. Organon (NYSE:OGN) today announced its results for the fourth quarter and full year ended December 31, 2025. "In 2025 we took action that demonstrate

    2/12/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

    Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its fourth quarter and full year 2025 financial results on February 12, 2026, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the fourth quarter of 2025. Organon's fourth quarter and full year 2025 results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing Fourth Quarter and Full Year 2025 F

    1/29/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Reports Results for the Third Quarter Ended September 30, 2025

    Third quarter 2025 revenue of $1.602 billion, up 1% as-reported and down 1% excluding the impact of foreign currency Third quarter 2025 diluted earnings per share of $0.61 and non-GAAP Adjusted diluted earnings per share of $1.01 Third quarter 2025 net income of $160 million and Adjusted EBITDA (non-GAAP) of $518 million, representing an Adjusted EBITDA margin of 32.3% Revenue guidance range for full year 2025 lowered to $6.200 billion to $6.250 billion; Adjusted EBITDA margin guidance lowered to ~31.0% Organon (NYSE:OGN) today announced its results for the third quarter ended September 30, 2025. "I am humbled to be working alongside our talented team during this pivotal time

    11/10/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care